Furthermore, tumor progression occurred with contrast-enhancing lesion and multiple masses during the third cycle of adjuvant TMZ treatment, implying that the tumor was perhaps refractory to TMZ, particularly with an unmethylated MGMT promoter. The gene discussed is MGMT; the disease is neoplasm.